ArticleCureus2026
Landscape of Apolipoprotein (APOE) in the Emirati Population and Recommendations for a Genotyping Approach for Amyloid-Beta Monoclonal Antibodies (Aβ-mAbs) in Alzheimer's Disease Patients.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApolipoprotein E (APOE) genotyping is increasingly recognized as a biomarker to support treatment decisions for Alzheimer's disease (AD) with the introduction of anti-amyloid monoclonal antibodies as promising therapeutic options. Although not yet incorporated into formal pharmacogenomic guidelines, regulatory authorities acknowledge its potential role in advancing precision medicine approaches.
methodsWe reviewed AD cases diagnosed in 2024 from the Department of Health - Abu Dhabi records and assessed monoclonal antibody prescribing patterns. APOE genotypes were determined using the two defining variants,
resultsIn 2024, 1,285 individuals were diagnosed with AD. Aducanumab was prescribed to eight patients between 2022 and 2024. In the Emirati Genome Program cohort, the allele frequencies of rs429358 and rs7412 were 8.3% and 4.2%, respectively. The most prevalent APOE genotype was ε3/ε3 (77.9%). The APOE ε4 risk allele was observed in 14.7% of participants, including 0.9% who were homozygous for ε4, while the protective APOE ε2 allele was present in 7.5%.
conclusionAPOE profiling supports genotype-informed treatment strategies for anti-amyloid therapies. These findings establish a population-specific framework for integrating genetic information into the Emirati Genome Program pharmacogenomic report, enhancing precision medicine approaches for AD management in the UAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.